|
[Related PubMed/MEDLINE]
Total Number of Papers: 80
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: PHD2 |
| Long Form |
: prolyl hydroxylase domain protein 2 |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
CHD1 deletion stabilizes HIF1α to promote angiogenesis and glycolysis in prostate cancer. |
Cas9, CHD1, CRISPR, GSEA, HIF1alpha, PCa, VHL |
| 2 |
2022 |
Differential methylation in EGLN1 associates with blood oxygen saturation and plasma protein levels in high-altitude pulmonary edema. |
EGLN1, HAPE, HIF1AN, HLs, SNM |
| 3 |
2022 |
Myeloid Angiotensin II Type 1 Receptor Mediates Macrophage Polarization and Promotes Vascular Injury in DOCA/Salt Hypertensive Mice. |
Ang, AT1R, DOCA, HIF, TLR |
| 4 |
2022 |
Oxygen sensors mediated HIF-1alpha accumulation and translocation: A pivotal mechanism of fine particles-exacerbated myocardial hypoxia injury. |
FIH-1, HIF-1alpha, IHD |
| 5 |
2022 |
Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations. |
EPO, HIFs, VHL |
| 6 |
2022 |
Screening prolyl hydroxylase domain 2 inhibitory activity of traditional Chinese medicine by CZE-UV. |
alpha-OG, CZE, HIF, TCM |
| 7 |
2022 |
The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells. |
Treg |
| 8 |
2022 |
The ribosomal chaperone NACA recruits PHD2 to cotranslationally modify HIF-α. |
HIF, NACA, PXLE |
| 9 |
2022 |
[Effect of Biantie pretreatment on serum level of PHD2/HIF-1alpha and brain tissue damage in rats during acute hypobaric hypoxia exposure]. |
DMOG, HIF-1alpha, Lac, VEGF |
| 10 |
2021 |
Carbon Monoxide is an Inhibitor of HIF Prolyl Hydroxylase Domain 2. |
CORM-2 |
| 11 |
2021 |
Congenital erythrocytosis. |
CE, EPAS1, EPO, HIF |
| 12 |
2021 |
HIF2alpha is a direct regulator of neutrophil motility. |
--- |
| 13 |
2021 |
HIF2alpha regulates the synthesis and release of epinephrine in the adrenal medulla. |
EPO, HIF, PNMT |
| 14 |
2021 |
WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1alpha accumulation in Myc-dependent and independent pathways. |
CCA, EMT, HDAC2, HIF-1alpha, MBIIIb, WDR5 |
| 15 |
2020 |
A small-molecule probe for monitoring binding to prolyl hydroxylase domain 2 by fluorescence polarisation. |
--- |
| 16 |
2020 |
Isolated Erythrocytosis Associated With 3 Novel Missense Mutations in the EGLN1 Gene. |
HIF-1 |
| 17 |
2020 |
Myocardium-targeted transplantation of PHD2 shRNA-modified bone mesenchymal stem cells through ultrasound-targeted microbubble destruction protects the heart from acute myocardial infarction. |
BMSCs, IGF, UTMD |
| 18 |
2020 |
Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo. |
alpha-SMA, BLM, CTGF, HIF, TGF-beta1 |
| 19 |
2019 |
An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23. |
HIF-2alpha |
| 20 |
2019 |
Update on mutations in the HIF: EPO pathway and their role in erythrocytosis. |
EPO, EPOR, HIF, VHL |
| 21 |
2018 |
Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinson's disease. |
DAergic SNpc, HIF1alpha, iPSC, PD |
| 22 |
2018 |
Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. |
--- |
| 23 |
2018 |
Regulation of Hypoxia-Inducible Factor 1alpha during Hypoxia by DAP5-Induced Translation of PHD2. |
DAP5, eIF4GI, HIF-1alpha, PKC |
| 24 |
2018 |
Small-molecules that covalently react with a human prolyl hydroxylase - towards activity modulation and substrate capture. |
--- |
| 25 |
2018 |
Transcriptome analysis demonstrates that long noncoding RNA is involved in the hypoxic response in Larimichthys crocea. |
HIF, lncRNAs |
| 26 |
2017 |
Ablation of endothelial prolyl hydroxylase domain protein-2 promotes renal vascular remodelling and fibrosis in mice. |
FSP-1, RI |
| 27 |
2017 |
Endothelial HIF-2alpha contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. |
EC, EndMT, HIF-2alpha, IPAH, KO, LVECs, PASMCs, PH, SMC |
| 28 |
2017 |
Hypoxia-inducible factor-1alpha activation in HPV-positive head and neck squamous cell carcinoma cell lines. |
HIF, HNSCC, HPV, IF |
| 29 |
2017 |
Prolyl Hydroxylase Domain-2 Inhibition Improves Skeletal Muscle Regeneration in a Male Murine Model of Obesity. |
HFD, RD, VEGF |
| 30 |
2017 |
Tet1 facilitates hypoxia tolerance by stabilizing the HIF-alpha proteins independent of its methylcytosine dioxygenase activity. |
HIF-alpha, TET |
| 31 |
2017 |
Uremic Toxins Affect the Imbalance of Redox State and Overexpression of Prolyl Hydroxylase 2 in Human Adipose Tissue-Derived Mesenchymal Stem Cells Involved in Wound Healing. |
CKD, CKD-AT-MSCs, HIF-1alpha, MSCs, nAT-MSCs, ROS |
| 32 |
2016 |
Activation of the hypoxia-inducible factor pathway induced by prolyl hydroxylase domain 2 deficiency enhances the effect of running training in mice. |
C/F, cKO, HIF |
| 33 |
2016 |
Expression and effect of proline hydroxylase domain 2 in retina of diabetic rats. |
GFAP, HE, IF, SD, SPF, VEGF |
| 34 |
2016 |
Homology modeling and molecular dynamics simulation of the HIF2alpha degradation-related HIF2alpha-VHL complex. |
DSSP, HIF2alpha, RMSD, SIE |
| 35 |
2016 |
miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning. |
HIF, IPC, IRI, LNA |
| 36 |
2016 |
Oxidative Dimerization of PHD2 is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1alpha Activation. |
HIF-1alpha |
| 37 |
2016 |
PHD2: from hypoxia regulation to disease progression. |
HIF |
| 38 |
2016 |
Prolyl hydroxylase 2 (PHD2) inhibition protects human renal epithelial cells and mice kidney from hypoxia injury. |
HIF-alpha |
| 39 |
2016 |
The Zinc Finger of Prolyl Hydroxylase Domain Protein 2 Is Essential for Efficient Hydroxylation of Hypoxia-Inducible Factor alpha. |
HIF-alpha |
| 40 |
2016 |
Tumour suppressor death-associated protein kinase targets cytoplasmic HIF-1alpha for Th17 suppression. |
DAPK, HIF-1alpha, Th17 |
| 41 |
2015 |
Acellular dermal matrix-based gene therapy augments graft incorporation. |
ADM, siRNA |
| 42 |
2015 |
Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. |
2OG, HIF1alpha |
| 43 |
2015 |
Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles. |
NP, siRNA-PA |
| 44 |
2015 |
HIF2alpha signaling inhibits adherens junctional disruption in acute lung injury. |
AJ, ARDS, ECs, VE-PTP |
| 45 |
2015 |
Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. |
CAFs, HIF |
| 46 |
2015 |
Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. |
EPO, REP, REP |
| 47 |
2014 |
HIF-1-PHD2 axis controls expression of syndecan 4 in nucleus pulposus cells. |
HIF-1alpha, HRE, HS, NP, SRY |
| 48 |
2014 |
Nanovector-based prolyl hydroxylase domain 2 silencing system enhances the efficiency of stem cell transplantation for infarcted myocardium repair. |
Arg-G4, MSC |
| 49 |
2014 |
Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia. |
CKD, HIF2, rHuEPO |
| 50 |
2014 |
Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection. |
AFP, DFS, HCC, OR, OS |
| 51 |
2013 |
Deletion of phd2 in myeloid lineage attenuates hypertensive cardiovascular remodeling. |
Ang II, HIF-alpha, L-NAME |
| 52 |
2013 |
Expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features. |
SCC, SK, VEGF |
| 53 |
2013 |
PHD2 regulates arteriogenic macrophages through TIE2 signalling. |
Ang-1 |
| 54 |
2013 |
Prolyl hydroxylase domain protein 2 (PHD2) binds a Pro-Xaa-Leu-Glu motif, linking it to the heat shock protein 90 pathway. |
HIF-alpha, Hsp90, MYND |
| 55 |
2013 |
Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium. |
ADSCs, IGF-1, shPHD2 |
| 56 |
2013 |
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. |
hi, TAM |
| 57 |
2012 |
Bafilomycin A1 activates HIF-dependent signalling in human colon cancer cells via mitochondrial uncoupling. |
CAIX, GLUT1 |
| 58 |
2012 |
Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. |
HIF |
| 59 |
2012 |
IDH1 mutations inhibit multiple alpha-ketoglutarate-dependent dioxygenase activities in astroglioma. |
5hmC, alpha-KG, IDH1, TET |
| 60 |
2012 |
Inverse solvent isotope effects demonstrate slow aquo release from hypoxia inducible factor-prolyl hydroxylase (PHD2). |
SIE |
| 61 |
2012 |
Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer. |
--- |
| 62 |
2012 |
Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH). |
alpha-KG, EPR, FIH, HIF |
| 63 |
2011 |
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. |
--- |
| 64 |
2011 |
Inhibition of a prolyl hydroxylase domain (PHD) by substrate analog peptides. |
FIH, HIF, PHD |
| 65 |
2011 |
Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. |
HIF, PHD |
| 66 |
2011 |
Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice. |
HIF |
| 67 |
2011 |
Topical prolyl hydroxylase domain-2 silencing improves diabetic murine wound closure. |
HIF, siRNA |
| 68 |
2009 |
2-Oxoglutarate analogue inhibitors of prolyl hydroxylase domain 2. |
--- |
| 69 |
2009 |
Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications. |
EPO, HIF-1a, VEGF |
| 70 |
2009 |
Erythrocytosis associated with a novel missense mutation in the HIF2A gene. |
EPO, HIF-alpha, VHL |
| 71 |
2009 |
Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck. |
HIF-1alpha, RT |
| 72 |
2009 |
Use of mass spectrometry to probe the nucleophilicity of cysteinyl residues of prolyl hydroxylase domain 2. |
ESI-MS |
| 73 |
2008 |
A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene. |
EpoR |
| 74 |
2008 |
Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. |
FGF-2, HIF-1, RNAi, VEGF |
| 75 |
2008 |
HIF in vascular development and tumour angiogenesis. |
HIF |
| 76 |
2008 |
PHD2 mutation and congenital erythrocytosis with paraganglioma. |
HIF, PHD |
| 77 |
2007 |
Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. |
--- |
| 78 |
2007 |
Hypoxia-inducible factor 1 (HIF-1) pathway. |
CBP, FIH-1, HIF-1, Hsp90, RACK1, VHL |
| 79 |
2006 |
Oxygen sensing: recent insights from idiopathic erythrocytosis. |
Epo, HIF, IE, VHL |
| 80 |
2006 |
Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation. |
ECs, HIF |
|
A Search Service for Abbreviation / Long Form
